



9th EUROD Winter Meeting

*CKD-associated osteoporosis and cardiovascular
disease in kidney transplantation*

January 14-16, 2026

Venue: Convent of Chièvres, Leuven, Belgium

Wednesday, January 14, 2026

13:00 – 14:30 Clinical Hot Topics: Cardiovascular

14:30 – 15:30: Poster Session 1

15:30 – 17:00: Clinical Hot Topics: Bone

18:30 – Meet & Greet in Leuven (KU Leuven, Zaal Couvereur, registration necessary)

Thursday, January 15, 2026

09:00 – 10:30: Clinical Workshop: Treating CKD-associated osteoporosis

10:30 – 11:00: Coffee Break

11:00 – 12:30: Symposium: Mineral Metabolism and Bone in Rare Renal Diseases

12:30 – 13:30: Lunch

13:30 – 15:00: Research Forum part 1

15:00 – 16:00: Poster Session 2

16:00 – 17:30: Research Forum part 2

19:00: Network Dinner (De Optimist, registration necessary)

Friday, January 16, 2026

CME: CKD-associated osteoporosis and cardiovascular disease in kidney transplantation

09:15 – 10:45 CKD-associated osteoporosis in kidney transplantation

10:45 – 11:30 Coffee Break & Faculty Photo

11:30 – 12:30 CKD-associated cardiovascular disease in kidney transplantation

12:30 – 13:30 Lunch

13:30 – 15:15 Treatment considerations

15:30 – 16:30 Coffee and Networking

Wednesday, January 14, 2026

This session aims to provide an update on the assessment and treatment of bone and vascular disease in CKD, by state-of-the-art lectures on current topics in the fields of CKD-associated cardiovascular disease and osteoporosis.

13:00 – 14:15 Clinical Hot Topics: Cardiovascular disease

Chairs: Smeeta Sinha (University of Manchester, United Kingdom) & Antonio Bellasi (Ospedale Regionale di Lugano Civico, Switzerland)

• 13:05 – 13:25: **Anti-coagulation in CKD: time to switch to DOAC?**

(Gunnar Heine, Saarland University Medical Center, Homburg, Germany)

• 13:30 – 13:50: **Calprotectin – true target or misnomer in vascular calcification?**

(Julie Klein, Université Toulouse III Paul-Sabatier, Toulouse, France)

• 13:55 – 14:15: **Metabolic acidosis: an appealing therapeutic target in CKD?**

(Nilufar Mohebbi, University Hospital, Zurich, Switzerland)

14:30 – 15:30: Poster Session 1

15:30 – 17:00: Clinical Hot Topics: Bone

Chairs: Hanne Skou Jørgensen (Aarhus University, Denmark) & Carlo Alfieri (University of Milan, Italy)

• 15:35 – 15:55: **Best clinical papers of 2025 in CKD-associated osteoporosis**

(Michael Laurent, Imelda General Hospital, Bonheiden, Belgium)

• 16:00 – 16:20: **EUROD Consensus 2025: utility of bone turnover markers in CKD**

(Mathias Haarhaus, Karolinska Institute, Stockholm, Sweden)

• 16:25 – 16:45: **Anabolic therapy – a promising option for CKD patients with high fracture risk?**

(Kassim Javaid, University of Oxford, United Kingdom)

18:30 – Meet & Greet in Leuven (KU Leuven, Zaal Couvereur, AGORA Learning Center, Edward Van Evenstraat 4, 3000 Leuvenm, Lokaal M01.E50)

Thursday, January 15, 2026

09:00 – 10:30: Clinical Workshop: Treating CKD-associated osteoporosis

Chairs: Mathias Haarhaus (Karolinska Institute, Stockholm, Sweden) & Marie-Helene Lafage-Proust (University of Lyon, St. Etienne, France)

CKD-associated osteoporosis remains a challenge for the clinician – evidence-based treatment and monitoring protocols are non-existent. Still, to address the treatment gap, and ease the fracture burden in our patient population, therapeutic nihilism must be avoided. This workshop will focus on practical treatment protocols of CKD-associated osteoporosis. Participants will discuss common clinical cases and strategies for treatment, monitoring and evaluation of therapeutic response with leading experts in the field. Participants rotate between two sessions of 40 minutes to discuss clinical cases in small groups, followed by Q&A with the session experts.

• 09:05 – 09:45 & 09:50 – 10:30: **Treatment algorithms in CKD-associated osteoporosis: anti-resorptive therapy – choice of agent, safety concerns and supportive treatment**

Expert panel: **Mathias Haarhaus**, Karolinska Institute, Stockholm, Sweden & **Marie-Helene Lafage-Proust**, University of Lyon, St. Etienne, France)

- 09:05 – 09:45 & 09:50 – 10:30: **Treatment algorithms in CKD-associated osteoporosis: anabolic and combination therapies – indications, choice of agent, safety concerns, monitoring and consolidation** (Expert panel: **Simona Barbuto**, University Hospital of Bologna IRCCS, Italy, **Thomas Nickolas**, Washington University School of Medicine, St Louis, United States)

10:30 – 11:00: Coffee Break

11:00 – 12:30: Symposium: Mineral metabolism and bone in rare renal diseases

Chairs: Agnieszka Prytula (Ghent University Hospital, Belgium) & Nathalie Bravenboer (University Medical Center Amsterdam, The Netherlands)

- 11:05 – 11:25: **Consequences of hypoparathyroidism: relevant for the nephrologist?**

(**Lucile Figueres**, CHU de Nantes, France)

- 11:30 – 11:55: **Indications and utility of PTH analogs in patients with hypoparathyroidism**

(**Jean Philippe Bertocchio**, University Hospitals Pitié Salpêtrière, Paris, France)

- 12:00 – 12:25: **Treatment of patients with X-linked hypophosphatemia: real-world data**

(**Dieter Haffner**, Hannover Medical School, Germany)

12:30 – 13:30: Lunch

13:30 – 17:30: Research Forum

The EUROD research forum gathers basic and clinical researchers, focusing on scientific progress in renal bone disease. The mission of the EUROD research forum is to share knowledge, foster collaboration, and enhance networking. The EUROD research forum comprises a mixture of invited mini lectures, selected free communications, and short pitches, with ample time for discussion.

13:30 – 15:00: Research Forum part 1

Chairs: Marie-Helene Lafage-Proust (University of Lyon, St. Etienne, France) & Anja Verhulst (University of Antwerp, Belgium)

- 13:30 – 13:45 (FC): **The landscape of renal osteodystrophy in Europe: A first report from the EUROD bone biopsy database** (**Ina Karstoft Ystrøm**, Aarhus University, Denmark)

- 13:45 – 14:05 (FC): **Bone turnover markers and bone balance index across stages of CKD**

(**Dieter Smout**, KU Leuven, Belgium)

- 14:05 – 14:20 (FC): **Fracture incidence and risk factors in a cohort of peritoneal dialysis patients**

(**Mariana Diz-Lopes**, Unidade Local de Saúde de São João, Porto, Portugal)

- 14:20 – 14:35 (FC): **Vitamin K2 supplementation improves endothelial health and kidney function in young renal transplant patients** (**Dominique Trouet**, University of Antwerp, Belgium)

- 14:35 – 14:55 (ML): **Conquering challenging conditions: creating European and global clinical trial networks in calciphylaxis** (**Smeeta Sinha**, University of Manchester, United Kingdom)

15:00 – 16:00: Poster Session 2

16:00 – 17:30: Research Forum part 2

Chairs: Nathalie Bravenboer (University Medical Center Amsterdam, The Netherlands) & Pieter Evenepoel (KU Leuven, Belgium)

- 16:00 – 16:15 (FC): **Bone mineral density and bone microarchitecture evolution after kidney transplantation: association with early changes in bone turnover biomarkers** (Antoine Bouquegneau, CHU Liège, Belgium)
- 16:15 – 16:30 (FC): **Characterisation of bone microstructure and material properties in chronic kidney disease: a case-control study** (Praopilad Srisuwarn, University of Sheffield, United Kingdom)
- 16:30 – 16:45 (FC): **Bone microarchitecture assessment using HR-pQCT in cystinuric patients: a cross-sectional study** (Andrea Spasiano, University of Verona, Italy)
- 16:50 – 17:10 (ML): **Synergy in clinic and research; how to organize your practice to support your research** (Hege Philstrøm, Oslo University Hospital Rigshospitalet, Norway)

17:15: Best Abstracts (Pieter Evenepoel, KU Leuven, Belgium)

19:00: Network Dinner (De Optimist, Vismarkt 7, 3000 Leuven)

Friday, January 16, 2026

CME: CKD-associated osteoporosis and cardiovascular disease in kidney transplantation

Kidney transplantation is the best treatment option for kidney failure; however, despite improvement in kidney function, complications related to CKD persist post-transplant. More than half of kidney transplant recipients exhibit ongoing disturbances of mineral metabolism, which may affect their risk of bone and vascular disease. These risks are compounded by the addition of immunosuppressive therapies. This CME will provide a contemporary view on bone and vascular disease in kidney transplantation, focusing on how to manage these conditions in relation to pre-transplant work-up and post-transplant care.

09:00 – 09:15 Welcome (Pieter Evenepoel, KU Leuven, Belgium)

09:15 – 10:45 CKD-associated osteoporosis in kidney transplantation

Chairs: Marie-Helene Lafage-Proust (University of Lyon, St. Etienne, France) & Anibal Ferreira (NOVA Medical School, Lisbon, Portugal)

- 09:15 – 09:35 **Bone health in kidney transplant candidates** (Carlo Alfieri, University of Milan, Italy)
- 09:40 – 10:00 **Impact of kidney transplantation on bone and mineral metabolism** (Hanne Skou Jørgensen, Aarhus University, Denmark)
- 10:05 – 10:25 **Bone health in paediatric kidney transplantation** (Agnieszka Prytula, Ghent University Hospital, Belgium)
- 10:30 – 10:45 **Panel Q&A**

10:45 – 11:30 Coffee Break & Faculty Photo

11:30 - 12:30: CKD-associated cardiovascular disease in kidney transplantation

Chairs: Maria Fusaro (University of Padova, Padova, Italy and National Research Council, Institute of Clinical Physiology, Pisa, Italy) & Hanne Skou Jørgensen (Aarhus University, Denmark)

- 11:30 – 11:50 **Cardiovascular health in kidney transplant candidates and recipients**

(**Antonio Bellasi**, Ospedale Regionale di Lugano Civico, Switzerland, Switzerland)

- 11:55 – 12:15 **Novel therapeutic options for cardiovascular health after kidney transplantation**

(**Martin de Borst**, University of Groningen, The Netherlands)

- 12:15 – 12:30 **Panel Q&A**

12:30 – 13:30 Lunch

13:30 - 15:15 Treatment considerations

Chairs: Pieter Evenepoel (KU Leuven, Belgium) & Mathias Haarhaus (Karolinska Institute, Stockholm, Sweden)

- 13:30 – 13:55 **Glucocorticoid-induced osteoporosis**

(**Julien Paccou**, Lille University Hospital, France)

- 14:00 – 14:25 **Precision medicine: balancing steroid exposure, rejection risk, and infections after kidney transplantation**

(**Dirk Kuypers**, KU Leuven, Belgium)

- 14:30 – 14:55 **Optimizing bone health after kidney transplantation**

(**Thomas Nickolas**, Washington University School of Medicine, St. Louis, United States)

- 15:00 – 15:15 **Panel Q&A**

15:15 Concluding remarks (Pieter Evenepoel, KU Leuven, Belgium)

15:30 – 16:30 Coffee and Networking

Posters sessions

Main hall, Poster session 1+2

1. Bone balance index as a risk marker for bone loss in the first post-transplant year (**Hanne Skou Jørgensen**, Aarhus, Denmark)
2. Bone balance index as a predictor of bone loss after kidney transplantation (**Antoine Bouquegneau**, Liege, Belgium)
3. High prevalence of sarcopenia, osteoporosis and osteosarcopenia in patients with chronic kidney disease compared with healthy controls (**Anahita Rashid**, Herlev, Denmark)
4. Bone balance and bone turnover in advanced CKD with renal osteodystrophy (**Syazrah Salam**, Sheffield, United Kingdom)
5. Screening and treatment of CKD-associated osteoporosis: A national survey (**Sukanya Sakthivel**, Aarhus, Denmark)
6. A longitudinal study on uremic vasculopathy and calcification in CKD rats (**Lama El-Haj**, Copenhagen, Denmark)
7. Integrating systematic ionized calcium measurement with dietary assessment improves calcium status management in hemodialysis patients (**Mohamed Tayeb Salaouatchi**, Brussels, Belgium)

Side hall, Poster session 1 (Wednesday)

8. Insights from novel bone turnover markers in CKD G5D (**Andrea Spasiano**, Verona, Italy)
9. Sex-related differences in the bone phenotype of kidney transplant candidates (**Maria Jesus Lloret**, Barcelona, Spain)
10. Assessment vertebral fractures and vascular calcifications in peritoneal dialysis patients (VERITA-PD study): A pilot study (**Althea Cossettini**, Milan, Italy)
11. Analytical impact of method-dependent variability in bone alkaline phosphatase immunoassays (**Mackowiac Alix**, Liege, Belgium)
12. Persistent hyperparathyroidism after kidney transplantation: prevalence and risk factors in a Belgian cohort (**Essalhi Hafsa**, Brussels, Belgium)
13. Sequential therapy in CKD: from concept to clinical opportunity (**Elena Rossi**, Bologna, Italy)
14. Trajectory and determinants of skeletal PTH hyporesponsiveness in CKD (**Guillaume Fernandes**, Leuven, Belgium)

Side hall, Poster session 2 (Thursday)

15. Nephrologists' survey on the management of chronic kidney disease-associated mineral and bone disorders in Switzerland (**Matthias Moor**, Bern, Switzerland)
16. BicMag trial protocol - Improving mineral buffering in dialysis patients (**Ursula Thiem**, Linz, Austria)
17. Preserved cortical bone sites and altered trabecular structure in patients with polycystic kidney disease after kidney transplantation (**Magdalena Jankowska**, Gdańsk, Poland)
18. Bridging the evidence gap in bone health for CKD: insights from an international survey (**Claudia Irene Maushart**, Oxford, United Kingdom)
19. Development of a method for quantifying fragments of parathyroid hormones by liquid chromatography coupled with tandem mass spectrometry (**Marine Piette**, Liege, Belgium)
20. Knowledge and practices regarding monitoring and treatment of CKD-MBD in Denmark – a survey among nephrologists (**Freja Stæhr Hassager**, Herlev, Denmark)
21. Effect of race, gender and age on intrinsic diurnal variation on serum calcifediol: Insights into vitamin D toxicity (**Charles W. Bishop**, Miami, United States)

Supported by unrestricted financial support by

Gold

CSL Vifor
OPKO RENAL

Silver

bridge**bio**

ids[®]
immunodiagnosticsystems



Inspired by **patients.**
Driven by **science.**

Bronze

ALEXION[®]
AstraZeneca Rare Disease

Alnylam[®]
PHARMACEUTICALS

AMGEN[®]

ascendis
pharma

KYOWA KIRIN

Theramex
For Women, For Health

With the support of

fwo

EUROD

Winter Meeting

Leuven, Belgium

Bones at the heart of CKD

